18th Mar 2008 10:30
AGI Therapeutics plc18 March 2008 AGI Therapeutics PLC Notification of Results AGI Therapeutics plc ("AGI" or the "Company") (AIM, IEX: AGI), a specialitypharmaceutical company focused on gastrointestinal drug products, will beannouncing its preliminary results for the year ended 31 December 2007 onThursday, 3 April 2008. An analyst briefing will be held at 09.30am on 3 April 2008 at the offices ofPiper Jaffray, One South Place, London EC2M 2RB. Contact Information: AGI Therapeutics plc. Tel: +353 1 449 3254David Kelly, Chief Financial Officer Financial Dynamics - UK Tel: +44 (0) 20 7269 7182Deborah Scott/Lara Mott Financial Dynamics - Ireland Tel: +353 1 663 3607Aisling Garvey Piper Jaffray Limited Tel: +44 (0) 20 3142 8700Neil MackisonWill Carnwath Davy Tel: +353 (1) 614 8761John Frain Notes to Editors: About AGI Therapeutics plc AGI is a speciality pharmaceutical company which is focused on the developmentand commercialisation of differentiated drug products for gastrointestinal (GI)diseases and disorders. AGI's common shares are listed on the AlternativeInvestment Market of the London Stock Exchange (AIM) and on the Irish EnterpriseExchange of the Irish Stock Market (IEX) as AGI. The Company has a portfolio of product candidates derived from its KnownMolecular Entity (KME) approach to drug re-profiling and development. TheCompany's lead product candidate, Rezular, is an orally administeredtriple-action intestinal regulator, a first-in-class mechanism for the treatmentof Diarrhoea predominant Irritable Bowel Syndrome, (IBS-D). Rezular iscurrently in Phase III clinical trials. KME is a re-profiling methodology used by the Company to identify existingtherapeutic drugs which typically have been marketed for a number of years, haveestablished safety profiles and can be developed for new clinical indications orwith improved profiles in their existing clinical indications. In this way, theCompany seeks to reduce the risk, time and cost of new product development ascompared to the development of new chemical entities. AGI is developing a range of product candidates to treat a variety of prevalentGI diseases and disorders, including irritable bowel syndrome (IBS), dyspepsia,gastroparesis, ulcerative colitis, gastro-esophageal reflux disease (GERD) anddiarrhoea-related conditions such as chemotherapy-induced diarrhoea (CID). TheCompany is targeting areas of the GI therapeutic drug products market for itsproduct candidates where there are currently unmet medical needs or where theeffectiveness of existing drug therapies can be further improved. The Company has five active clinical stage product candidates which are eitherisomers or new drug delivery formulations of existing approved drugs, and whichhave established safety and tolerability profiles in their currently approvedclinical indications. For further information please see www.agitherapeutics.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Potentially Ai